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doi:10.1016/j.ejvs.2008.06.020Abstract Background: Endovascular therapy is a rapidly expanding option for the treatment
of patients with peripheral arterial disease (PAD), leading to a myriad of published studies
reporting on various revascularization strategies. However, these reports are often difficult
to interpret and compare because they do not utilize uniform clinical endpoint definitions.
Moreover, few of these studies describe clinical outcomes from a patients’ perspective.
Methods and results: The DEFINE Group is a collaborative effort of an ad-hoc multidisciplinary
team from various specialties involved in peripheral arterial disease therapy in Europe and the
United States. DEFINE’s goal was to arrive at a broad based consensus for baseline and
endpoint definitions in peripheral endovascular revascularization trials for chronic lower limb
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410 N. Diehm et al.existing pertinent literature. Following this, a series of telephone conferences and face-to-
face meetings were held to agree upon definitions. Input was also obtained from regulatory
(United States Food and Drug Administration) and industry (device manufacturers with an
interest in peripheral endovascular revascularization) stakeholders, respectively. The efforts
resulted in the current document containing proposed baseline and endpoint definitions in
chronic lower limb PAD. Although the consensus has inevitably included certain arbitrary
choices and compromises, adherence to these proposed standard definitions would provide
consistency across future trials, thereby facilitating evaluation of clinical effectiveness and
safety of various endovascular revascularization techniques.
Conclusion: This current document is based on a broad based consensus involving relevant
stakeholders from the medical community, industry and regulatory bodies. It is proposed that
the consensus document may have value for study design of future clinical trials in chronic
lower limb ischemia as well as for regulatory purposes.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Endovascular therapy is a rapidly evolving option for the
treatment of patients with peripheral arterial disease
(PAD).1 The excitement generated by the prospects of
new technology has led endovascular therapists of various
specialty backgrounds to pursue innovative approaches uti-
lizing minimally invasive arterial revascularization.
Clinical trials are of utmost importance in the
assessment of new technologies to ascertain clinical effi-
cacy and safety, thereby prompting adoption for clinical
use following regulatory approval. A number of clinical
studies assessing technologies in endovascular lower limb
arterial revascularization have recently been published.
However, substantial variability in endpoint definitions has
created a significant barrier for comparison of results across
these trials.2 Moreover, previous studies on lower limb
peripheral arterial revascularization have rarely described
clinical outcomes from a patients’ perspective.2
The DEFINE Group was founded in 2006, consisting of
a broad interdisciplinary team (interventional angiologists,
cardiologists and radiologists as well as vascular surgeons, an
endovascular neurosurgeon and non-invasive vascular medi-
cine specialists) from Europe and the United States. The
mission of this first DEFINE effort was to create a set of
definitions whichwould increase consistency in future periph-
eral endovascular revascularization trials. The DEFINE Group
reviewed the present literature and, after extensive corre-
spondence andmeetings, proposed the definitions outlined in
the presentmanuscript. Twomeetings including all authors of
the manuscript, along with representatives of the United
States Food and Drug Administration (FDA) and commercial
device manufacturers were held in Washington, DC, in July
2007 and in New York, NY, in November 2007. Several
teleconferences were also required to continue the process.
Key components of this effort included definitions for
baseline clinical and anatomic characteristics, clinical out-
comes relevant to the patients, morphologic outcomes, and
complications. Existing standards for reporting lower ex-
tremity ischemia were modified and updated, if necessary,
to apply specifically to peripheral endovascular procedures
and to reflect new insights that have emerged over the last
decade.2e5 Given the contribution by the multidisciplinary
scientific members and the regulatory authorities, wehope that the definitions described in the present manu-
script will be applicable for future clinical investigations.
Proposed Baseline and Endpoint Definitions
Patient clinical and anatomical baseline
characteristics
Baseline definitions include descriptions of clinical patient
characteristics and of the characteristics of the vascular
lesion(s) that are to be treated with the endovascular
therapy under investigation.
Pre-treatment evaluation should include objective and
quantitative measures of disease severity, measurement of
functional status and a description of known atheroscle-
rotic risk factors which may have an impact on procedural
and clinical outcomes (Table 1).
Clinical evaluation
Patients with intermittent claudication (IC) and those with
critical limb ischemia (CLI) should be evaluated separately
in outcomes analyses. Baseline clinical evaluations should
include anatomic descriptions and functional status, as well
as quality of life.
Functional status at baseline
Disease severity in patients with chronic lower limb
ischemia should be objectively described according to
criteria proposed by Rutherford (Appendix).3
Functional status must be quantified by standardized
treadmill testing using a graded exercise treadmill protocol
(speed constant at 2miles per hour [3.2 km/h], 2% increase in
grade every 2 minutes) in all patients studied for IC.6 This
treadmill test should be performed until claudication pain
occurs or to amaximumof 5minutes. Changes in claudication
onset time (COT: time after initiation of exercise when the
patient first experienced symptoms of claudication) and
absolute claudication time (ACT: time after initiation of
exercise until he/she can not walk further due to severe
claudication pain) are to be reported inminutes and seconds.
Patients who are not able or willing to undergo standardized
treadmill testing should be excluded from IC trials.
Table 1 Patient clinical and anatomical baseline
characteristics
 Separate outcome reporting for patients with
claudication and critical limb ischemia.
 Rutherford stages at baseline.
 In claudicants: standardized treadmill testing (2 miles
per hour [3.2 km/h] at a 12% grade or 2 miles per hour
[3.2 km/h] with 2% increase in grade every 2 minutes);
claudication onset time (COT) and absolute claudication
time (ACT).
 Quality of life at baseline: EuroQOL 5 Dimension.
 Walking ability: walking impairment questionnaire.
 In claudicants: ankle-brachial index (ABI) at rest
and after exercise.
 In patients with critical limb ischemia: systolic ankle
pressure and ABI.
 Oscillographic reading or toe pressure measurement if
ABI cannot be appropriately measured.
 Risk factors and comorbidities: Age, gender, race,
hypertension, hyperlipidemia, diabetes mellitus, smoking,
ischemic heart disease, congestive heart failure, renal
insufficiency, cerebrovascular disease.
 Medication:,Anticoagulants, antithrombotic agents,
statins, beta-blockers, angiotensin converting enzyme
inhibitors, angiotensin-II receptor antagonists.
 Anatomic levels, arterial segments, arterial in- and
outflow, involvement of arterial origin/ostium, lesion
length, degree of obstruction (as determined by
intra-arterial pressure measurement, intravascular
ultrasound, angiography, magnetic resonance or
computed tomography angiography or by duplex
ultrasound, calcification (none, moderate, heavy).
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The EuroQol 5 Dimensions (EQ5D) is recommended to be
used to measure quality of life,7 whereas the walking
impairment questionnaire is recommended to assess walk-
ing distance and speed of patients with IC.7,8
Hemodynamic evaluation at baseline
In patients with IC, ankle brachial index (ABI) measure-
ments at rest and after treadmill exercise (after reaching
the absolute claudication distance, ACD) should be
performed according to the AHA recommendations.5,9 In
patients with CLI, only systolic ankle pressure, ABI and
digital pressures or photoplethysmographic waveforms
at rest are required.
In scenarios in which the ABI cannot be measured, such as
in case ofmedial arterial calcification (e.g. diabetesmellitus
or renal insufficiency), photoplethysmographic or oscillo-
metric reading or toe pressure measurement and determi-
nation of the toe brachial index should be used.3,5,10
Risk factors and comorbidities
The following risk factors and comorbidities should be
recorded:
 Age
 Gender
 Race Hypertension, as defined by the Joint National Commit-
tee on Prevention, Detection, and Treatment of High
Blood Pressure11 or if the patient is on antihypertensive
therapy for the indication of hypertension:
- Normal blood pressure: systolic< 120 mmHg and
diastolic< 80 mmHg
- Prehypertension: systolic 120e139 mmHg or diastolic
80e89 mmHg
- Stage 1 hypertension: systolic 140e159 mmHg or dia-
stolic 90e99 mmHg
- Stage 2 hypertension: systolic 160 mmHg or
diastolic 100 mmHg
 Hyperlipidemia: Patients with hyperlipidemia as
defined by the accepted standards or National
Cholesterol Education Program Adult Treatment Panel
III or if patient is taking blood lipid-lowering medication
for the indication of hyperlipidemia12
 Diabetes mellitus: HbA1c> 7% or if or if patient
consumes oral hypoglycaemic agents13
 Smoking: Current smoking status (active/previous/
never), and if ever smoked, include number of pack
years (i.e. number of packs smoked daily multiplied
by the number of years smoked), as well as the number
of years since the patient last smoked tobacco
 Ischemic heart disease14: History of myocardial infarc-
tion (Q or non-Q wave MI), angina pectoris, previous
percutaneous or surgical coronary revascularization,
positive exercise test, anti-anginal therapy
 Congestive heart failure (according to New York Heart
Association Classification I to IV, ejection fraction<40%)
 Renal insufficiency: glomerular filtration rate< 60 ml/
min (calculated according to Cockcroft formula15)
 Cerebrovascular disease: known carotid artery disease
and history of minor or major stroke or transient ische-
mic attack (TIA)Medication usage
Pre-, peri-, and post-procedural medications should be
specified as follows (including generic name, dose, fre-
quency, and (if possible) duration of use):
 Anticoagulants (warfarin, unfractioned or low molecu-
lar weight heparins, etc)
 Antithrombotic agents (acetylic salicylic acid, clopidog-
rel, ticlopidine, glycoprotein IIb/IIIa inhibitors, direct
thrombin inhibitors, etc)
 Statins or other lipid lowering agents
 Beta-blockers
 Angiotensin converting enzyme inhibitors
 Angiotensin-II receptor antagonists
 Insulin and oral hypoglycaemic agents
 Medications for the treatment of IC (ie cilostazol,
pentoxifylline, etc.)
Baseline anatomic characteristics
Baseline anatomic characteristics should be reported for
all enrolled patients: anatomic levels, arterial segments,
inflow, outflow, involvement of ostium, along with
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lesion length, stenosis or occlusion; degree of thrombus
and calcification. The TASC lesion classification,10,16 al-
though commonly utilized, may not be the ideal
schema,17 and we suggest a more complete description
of the arterial lesion.
Anatomic levels
 aortoiliac level (distal limit: deep circumflex iliac
artery, inguinal ligament)
 femoropopliteal level (distal limit: origin of anterior
tibial artery)
 crural level (including foot arteries)
Multilevel disease is defined as presence of significant
obstructive lesions at more than one level. The right and
left leg are considered separately. Thus, the combination of
a lesion in the left common iliac combined with a lesion in
the left popliteal artery equals multilevel disease, whereas
presence of a lesion in the left common iliac combined with
a lesion in the right popliteal artery is considered bilateral
single level disease.
Arterial segments
Segments refer to specific locations in which patient out-
comes of endovascular therapy may differ. The following
segments should be differentiated:
 Infra-renal abdominal aorta
 Common iliac artery
 Internal iliac artery
 External iliac artery
 Common femoral artery
 Deep femoral (profunda femoris) artery
 Superficial femoral artery (ends upon exiting adductor
canal of Hunter angiographic approximation: crossing
of artery over medial cortex of femur when viewed in
an anterior-posterior projection).
 Popliteal artery, subdivided into:
- P1 segment (above knee popliteal artery): from
Hunter’s canal to proximal edge of patella
- P2 segment: from proximal part of patella to center
of knee joint space
- P3 segment (below knee popliteal artery): from
center of knee joint space to origin of anterior
tibial artery
 Tibioperoneal trunk (from the origin of the anterior
tibial artery to the bifurcation of the posterior tibial
and peroneal artery)
 Proximal anterior tibial artery (from origin to longitudi-
nal midpoint of the tibial shaft)
 Proximal posterior tibial artery (from origin to longitu-
dinal midpoint of the tibial shaft)
 Proximal peroneal artery (from origin to longitudinal
midpoint of the tibial shaft)
 Distal anterior tibial artery (from the longitudinal mid-
point of the tibial shaft to the level of the upper part of
the tibio-talar joint space)
 Distal posterior tibial artery (from the longitudinal mid-
point of the tibial shaft to the level of the distal tip of
the medial malleolus) Distal peroneal artery to (from the longitudinal mid-
point of the tibial shaft to it’s normal terminus above
the ankle mortise).
 Dorsalis pedis artery (distal to the tibio-talar joint
space)
 Posterior tibial artery at foot level (distal to the tibio-
talar joint space)
 Plantar and pedal foot arcades
 Digital arteriesArterial inflow and outflow
Arterial inflow is defined with regard to the above-defined
anatomic levels (2.5.1). The inflow to a vascular lesion at
a certain level refers to the combined levels proximal to
the lesion. Thus, for a lesion in the superficial femoral
artery (i.e. femoropopliteal level), arterial inflow refers
to the common femoral artery and the aortoiliac level.
For a lesion in the anterior tibial artery (i.e. crural level),
inflow refers to both the aortoiliac and femoropopliteal
levels. Good inflow implies straightline vessels proximal to
a site that are free of hemodynamically significant obstruc-
tion (i.e. 50% stenosis) of the inflow arteries.
Impaired inflow means that the vessels proximal to the
site contain hemodynamically significant lesions (i.e.50%),
whereas impaired inflow represents the presence of such
lesions. Arterial outflow is defined accordingly, with the
outflow of a vascular lesion being defined as the combined
levels distal to a lesion. The superficial and deep femoral
arteries are the runoff vessels for iliac artery procedures,
and the tibial arteries are the runoff vessels for femoropo-
pliteal procedures.
For further definition of below-the-knee outflow, the
number of patent arteries with patency directly to the foot
arteries should be specified. Thus, for a lesion in the
superficial femoral artery (i.e. femoropopliteal level) with
an occlusion of the peroneal artery, arterial outflow should
be ‘‘2-vessel outflow’’. Moreover, to define arterial outflow
in the foot, the patency of both the dorsal and plantar
pedal arch should be specified (‘‘yes/no’’).
Involvement of arterial origin/ostium
It should be provided whether or not the lesion involves the
origin/ostium of a specific artery.
Lesion length
We propose to define the following lesion lengths for use in
all segments that apply to stenoses and occlusions alike:
 Focal lesions: 1 cm
 Short lesions: >1 and< 5 cm
 Intermediate lesions: 5 cm and< 15 cm
 Long lesions: 15 cm
In case of vessel occlusion within a stenosed segment,
both the length of the stenosed segment and the length of
the occluded segment should be reported.
Degree of obstruction
Hemodynamic significance of a lesion can be assessed
utilizing the following measurement techniques (listed in
a hierarchical order):
Table 2b Clinical outcome in patients treated for
claudication
 Distribution of Rutherford stages during follow-up as
compared to baseline.
 Changes in claudication onset time (COT) and absolute
claudication time (ACT).
 Change in quality of life according to EuroQOL.
 Change in walking ability according to walking
impairment questionnaire.
 Primary sustained clinical improvement (sustained upward
shift of 1 category on Rutherford classification without
the need for repeated target lesion revascularization
(TLR) in surviving patients).
 Secondary sustained clinical improvement (sustained
upward shift of 1 category on Rutherford classification
including the need for repeated TLR in surviving patients.
 Primary sustained resolution of symptoms from PAD
(sustained absence of claudication without the need for
repeated TLR in surviving patients).
 Secondary sustained resolution of symptoms from PAD
(sustained absence of claudication including the need
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pressure gradient >10 mmHg at rest or during pharma-
cological dilatation of the arterial bed (by papaverine,
tolazolin, nitroglycerine, or a similar substance) as
assessed by means of two simultaneous measurements
using two pressure channels proximally and distally to
the lesion.
2.) Intravascular ultrasound (IVUS) measurements in-
dicating 50% diameter stenosis or 75% area stenosis.
3.) Intra-arterial digital subtraction angiography in-
dicating 50% diameter stenosis by visual estimation
or by quantitative vessel analysis software assessing at
least two different angiographic projections.
4.) Contrast-enhanced magnetic resonance or multi-slice
computed tomography angiography using state-of-the-
art imaging protocols indicating 50% diameter stenosis
or 75% area stenosis.
5.) Duplex ultrasound indicating 50% diameter stenosis as
defined by a peak systolic velocity index (defined as the
ratio of intra-stenotic peak systolic velocity to pre-
stenotic peak systolic velocity)> 2.4.18for repeated TLR in surviving patients).
 Clinical deterioration (downgrade of 1 category on the
Rutherford classification after endovascular treatment).
 Immediate hemodynamic improvement: increase in
ABI of 0.10 or to an ABI 0.9.
 Sustained hemodynamic improvement: persistent
improvement of ABI-values with  0.10 as compared to
baseline values or to ABI  0.9 throughout follow-up
without need for repeated TLR in surviving patients.
 30-day (procedure-related and all-cause) mortality and
mortality during follow-up.
 Need for minor (below the ankle) and major (above the
ankle) unplanned amputation. Major amputation specified
as below-the-knee and above-the-knee amputations.
Planned versus unplanned amputations.Calcification
A semi quantitative distinction between no, moderate, and
heavy calcification at the site of the lesion should be
provided according to findings on the fluoroscopic image
obtained prior to the intervention.
Endpoint Definitions: Clinical Outcomes and
Complications
Endpoint definitions encompass immediate procedural
success, complications, and clinical outcome during fol-
low-up (Tables 2aed). All failures occurring within 30 days
of the procedure (i.e. absence of procedural success) are
considered ‘‘acute procedural failures’’, and are attributed
to the procedure. To evaluate clinical outcomes we propose
aminimum follow-up period of 12 months, which is consid-
ered short-term follow-up. Mid-term follow-up refers to
follow-up periods of greater than 1 year to 3 years and
long-term follow-up to be greater than 3 years of post-
procedural follow-up. Special care was taken to grant
applicability of clinical outcome definitions (chapters 3.2
and 3.3) also to trials assessing the efficacy of open surgical
revascularization.Table 2a Immediate outcome
 Procedural success: Combination of technical success,
device success and absence of procedural complications.
 Technical success: successful vascular access and
completion of the endovascular procedure and
immediate morphological success with less than 30%
residual diameter reduction of the treated lesion on
completion angiography.
 Device success: exact deployment of the device
according to the instructions for use as documented
with suitable imaging modalities and in case of digital
subtraction angiography, in at least two different
imaging projections.Procedural success
Technical or device success is defined as achievement of
a final residual diameter stenosis of <30% on the procedural
completion angiogram, using the assigned device only,
whereas lesion success is defined as achievement of <30%
residual stenosis using any percutaneous method.
Procedural success is technical or device success
without the occurrence of major adverse events during
the hospital stay.
Clinical outcomes for treatment of IC
Change in functional status in patients treated for IC
Change in disease severity should be described according to
the categories proposed by Rutherford (Appendix).3
Change in walking capacity should be assessed to
measure the objective functional response to therapeutic
interventions according to the above-mentioned standard-
ized treadmill protocols:2,10,16 Changes in claudication
onset time (COT, defined as the time after initiation of
exercise when the patient first experienced symptoms of
claudication) and absolute claudication time (ACT, defined
as the time after initiation of exercise until he/she can not
Table 2d Complications
 Adverse events (AE).
 Serious adverse events (SAE).
 Adverse device effect.
 (Serious) Adverse device effect (SADE).
 Unanticipated adverse device effect (UADE).
 Major Adverse Event (MAE).
Examples of complications according to different
categories
 Access site complication:
Hematoma/bleeding; arterial/venous occlusion/
thrombosis; severe vasospasm; intimal injury/dissection;
pseudoaneurysm; AV fistula; vascular perforation or
rupture; arterial embolizations at puncture site.
 Vessel specific complication:
Hematoma/bleeding; arterial/venous occlusion/
thrombosis; severe vasospasm; intimal injury/dissection;
pseudoaneurysm; AV fistula; vascular perforation or
rupture; arterial embolizations remote from puncture site.
 Organ specific complication:
- Neurological: TIA, Minor and major stroke, seizure.
- Cardiovascular: Hypotension or hypertension requiring
treatment, arrhythmia requiring treatment, myocardial
ischemia/infarction, chronic heart failure.
- Respiratory: Profound Hypoxia, pulmonary edema,
respiratory arrest, pulmonary embolism, pneumothorax,
local infection, septicemia/bacteremia.
- Gastrointestinal: Gastric bleeding, pancreatitis,
peritonitis, abscess, unintended perforation of hollow
viscus.
 Systemic complication:
Allergic/anaphylactoid reaction, renal failure, tissue ex-
travasation, idiosyncratic reaction to drug, fluid/
electrolyte imbalance.
Table 2c Clinical outcome in patients treated for critical
limb ischemia
 Distribution of Rutherford stages during follow-up as
compared to baseline.
 Change in quality of life according to EuroQOL.
 Primary sustained clinical improvement (upward shift
on the Rutherford classification to a level of claudication
without the need for repeated TLR in surviving patients
without the need for unplanned amputation).
 Secondary sustained clinical improvement (upward shift
on the Rutherford classification to a level of claudication,
including the need for repeated TLR in surviving patients
without the need for unplanned amputation).
 Clinical deterioration (downgrade of 1 category on the
Rutherford classification after endovascular treatment).
 Immediate hemodynamic improvement: increase
in ABI of 0.10 or to an ABI 0.9.
 Sustained hemodynamic improvement: persistent
improvement of ABI-values with  0.10 as compared to
baseline values or to ABI  0.9 throughout follow-up
without need for repeated TLR in surviving patients.
 30-day (procedure-related and all-cause) mortality and
mortality during follow-up.
 Need for minor (below the ankle) and major (above the
ankle) unplanned amputation. Major amputation specified
as below-the-knee and above-the-knee amputations.
Planned versus unplanned amputations.
414 N. Diehm et al.walk further due to severe claudication pain) must be
reported in minutes and seconds.
Change in disease severity in patients treated for IC
Sustained clinical improvement has to be regarded
a primary clinical endpoint in trials assessing outcomes of
patients with IC.2 Primary sustained clinical improvement
is defined as sustained upward shift of at least one category
on the Rutherford classification3 (Appendix) without the
need for repeated target lesion revascularization (TLR) in
surviving patients (i.e. dead patients will be censored at
the time point when they were last examined). Secondary
sustained clinical improvement is defined as sustained
upward shift of at least one category on the Rutherford
classification3 (Appendix) including the need for repeated
TLR in surviving patients.
Moreover, primary sustained resolution of symptoms
from PAD is defined as sustained absence of IC without
the need for repeated TLR in surviving patients. In contrast,
secondary sustained resolution of symptoms from PAD
describes sustained absence of IC including the need for re-
peated TLR in surviving patients.
Clinical deterioration should be described as a down-
grade of 1 category on the Rutherford classification (Ap-
pendix) as a result of endovascular treatment
(improvements that occur after secondary procedures are
not included, i.e. this endpoint does not include repeated
TLR/TER). Furthermore, distribution of clinical stages
according to Rutherford3 (Appendix) during all follow-up
visits should be given as compared to baseline.2
No change in functional outcome will be captured as
absence of primary or secondary sustained clinical improve-
ment or absence of deterioration. Thus, in the cumulativeanalysis for primary or secondary sustained clinical im-
provement patients not experiencing any change in the
Rutherford classification (Appendix) will have to be uncen-
sored, whereas they will have to be censored in the analysis
for clinical deterioration.
Clinical outcomes for treatment of critical limb
ischemia (CLI)
Change in functional status in patients treated for CLI
Change in disease severity should be described according to
the categories of the criteria proposed by Rutherford
(Appendix).3
Change in disease severity in patients treated for
CLI
Sustained clinical improvement has to be regarded
a primary clinical endpoint.2 Treadmill testing is not re-
quired in patients treated for CLI. Primary sustained
clinical improvement is defined as an upward shift on
the Rutherford classification (Appendix) to a level of IC
without the need for repeated TLR in surviving patients
without the need for unplanned amputation. Secondary
sustained clinical improvement is defined as an upward
Uniform Reporting Studies for Peripheral Endovascular Revascularization 415shift on the Rutherford classification (Appendix) to
a level of IC, including the need for repeated TLR in
surviving patients without the need for unplanned
amputation.
Clinical deterioration is defined as a downgrade of 1
category on the Rutherford classification (Appendix) as a re-
sult of endovascular treatment (improvements that occur
after secondary procedures are not included, i.e. this end-
point does not include repeated TLR/TER). Furthermore,
distribution of clinical stages according to Rutherford3
(Appendix) during all follow-up visits should be given as
compared to baseline.2
No change in functional outcome will be captured as
absence of primary or secondary sustained clinical improve-
ment or absence of deterioration. Thus, in the cumulative
analysis for primary or secondary sustained clinical im-
provement patients not experiencing any change in the
Rutherford classification (Appendix) will have to be uncen-
sored, whereas they will have to be censored in the analysis
for clinical deterioration.
Hemodynamic outcome
Immediate hemodynamic improvement after endovascu-
lar revascularization is defined as ankle brachial index
(ABI) improvement of 0.10 or to an ABI 0.9.
Sustained hemodynamic improvement is defined as
persistent improvement of ABI-values with  0.10 as com-
pared to baseline values or to an ABI  0.9 throughout fol-
low-up without the need for repeated target lesion
revascularization (TLR) in surviving patients (i.e. patients
that died have to be censored in this analysis).3
Desirable for review of data quality is the declaration of
mean and median ABI at all follow-up visits as compared
to baseline.
In case ABI cannot be appropriately measured such as
in patients with medial arterial calcification (e.g.
diabetes mellitus or renal insufficiency), photoplethysmo-
graphic or oscillometric determination of toe pressure
with the calculation of the toe-brachial index should be
used.3,5,10
Mortality
Causes of death associated with the endovascular
procedure (procedure related mortality, i.e. mortality
within 30 days post-procedure or mortality during a hospi-
talization> 30 days due to the procedure) should be
reported separately as well as overall mortality.2
Amputation
Need for minor (below the ankle) and major (above the
ankle) unplanned amputation have to be regarded as
major outcome criteria in trials, but should be reported
separately for patients with IC and chronic CLI.2 Major
amputation rates should be reported and specified as
below-the-knee and above-the-knee amputations. Further-
more, planned and unplanned amputations should be
reported separately.Complications
Complications should be reported according to the general
clinical research guidelines and the applicable (local) laws.
For this purpose, reference is made to the International
Society for Standardization (ISO) 14155,19 the International
Conference on Harmonisation-Good Clinical Practice (ICH-
GCP) guidelines20 and the Food and Drug Administration
(FDA) 21 Code of Federal Regulations (CFR) chapter
x812.3.21
The primary mode of action of the investigational
product as well as the region where the trial is performed
will determine which regulations must be used. Addition-
ally, combined products or non-medical devices such as cell
therapy may require using a combination of these
guidelines.
Any untoward occurrence in a subject should be differ-
entiated as follows:
 Adverse events (AE)
 Serious adverse events (SAE)
 Adverse device effect
 (Serious) Adverse device effect (SADE)
 Unanticipated adverse device effect (UADE)
 Major Adverse Event (MAE)
In case the investigational product is classified different
than a medical device, other general definitions may be
applicable (e.g. Suspected Unexpected Serious Adverse
Reaction [SUSAR]).
Adverse events (AE) - ISO 14155-1 (3.2)
An AE is defined as any untoward medical occurrence in
a subject.
This definition, however, does not imply that there is
a relationship between the adverse event and the device
under investigation.
Serious adverse event (SAE) - ISO 14155-1 (3.19)
A SAE is an AE that
 led to a death.
 led to a serious deterioration in the health of the
subject that
- resulted in a life-threatening illness or injury.
- resulted in permanent impairment of a body struc-
ture or a body function.
- required inpatient hospitalization or prolongation of
existing hospitalization.
- Resulted in medical or surgical intervention to pre-
vent permanent impairment to body structure or
bodily function.
 led to fetal distress, fetal death or a congenital abnor-
mality or birth defect
All AEs whether or not serious must be rated ‘‘related or
unrelated to the investigational product’’.
Adverse device effect - ISO 14155-1 (3.1)
An adverse device defect is defined as any untoward and
unintended response to a medical device. This definition
Table 3 Morphologic outcome
 Cumulative rates of absence of binary restenosis ( 50%
re-obstruction of the target lesion) and rates of
reocclusions as assessed by:
- Intra-arterial angiography in at least two different
projections (preferably with quantitative vessel analysis).
- IVUS measurements indicating 50% diameter stenosis
or 75% area stenosis can be used to determine
restenosis.
- Duplex ultrasound (peak systolic velocity index greater
than 2.4 at the target lesion).
- Magnetic resonance and computed tomography
angiography (pending positive results from accuracy
studies assessing their ability to quantify arterial
obstructions as outlined above).
 Repeated target lesion revascularization (TLR) rate.
 Repeated target extremity revascularization (TER) rate.
 Reporting of device-specific problems such as stent
fractures.
 Independent core laboratory analysis of arterial imaging is
warranted.
416 N. Diehm et al.includes any event resulting from insufficiencies or in-
adequacies in the instructions for use or the deployment
of the device as well as any event that is a result of a user
error.
Serious adverse device effect - ISO 14155-1 (3.19)
A serious adverse device effect is defined as adverse device
effect that has resulted in any of the consequences
characteristic of a serious adverse event or that might
have led to any of these consequences if suitable action had
not been taken or intervention had not been made or if
circumstances had been less opportune.
Unanticipated adverse device effect - FDA 21
CRF x 812.3 (s)
Any serious adverse effect on health or safety or any life-
threatening problem or any life-threatening problem or
death caused by, or associated with, a device if that effect,
problem, or death was not previously identified in nature,
severity, or degree of incidence in the investigational plan
or application (including a supplementary plan or applica-
tion), or any other unanticipated serious problem associ-
ated with a device that relates to the rights, safety or
welfare of subjects is defined as an unanticipated adverse
device effect.
Major Adverse Event (MAE)
The MAE definition is different for each protocol and must
be defined in the protocol.
It is recommended to use an independent committee
(Clinical Event or Data Safety and Monitoring Committee)
for the adjudication of the SAEs to determine if an event is
a MAE or not. The CEC may define, prior to the start of the
study, the type of events that will be reviewed and
adjudicated.
All AEs and SAEs must appear in the final report.
Information related to the adjudication of the events may
be added. Reporting by the manufacturer/sponsor to the
regulatory bodies must be performed according the spec-
ified national regulations.
The following Major Adverse Event definition is
recommended for studies involving patients with peripheral
vascular disease:
 All deaths.
 Major amputation, planned and unplanned.
Additionally, the following occurrences should appear in
the related publication or at a minimum in the final trial
report:
 Procedural related serious adverse events.
 Investigational product related serious adverse events.
 Device failure or malfunction.
Next to the MAE, the reported (serious) adverse events
should be classified and reported according to the following
four complication categories: access site complications,
vessel specific complications (treatment site including
distal to the site), organ-specific complications, systemic
complications (Table 2d).Morphologic Outcome
We suggest replacing the term ‘‘patency’’ with ‘‘absence
of binary restenosis’’, which equals 50% re-obstruction
of the target lesion (Table 3). Moreover, cumulative
rates of reocclusions (defined as complete occlusion of
the initially treated target lesion).
We suggest that independent core laboratory analysis
of angiographic and duplex ultrasound images be manda-
tory for assessment of new devices.
Intra-arterial angiography remains the current gold
standard for depiction of lesions in peripheral arteries.5
Precise quantitative angiographic assessment of the target
lesion with objective measures such as the percent diame-
ter stenosis relative to the adjacent arterial segments is
warranted.
Especially in trials comparatively reporting on different
peripheralendovascular revascularization strategies (i.e.using
stents or other devices aiming at the prevention of restenosis)
angiographic analysis using quantitative vessel analysis
software derived from the methods established for coronary
artery analysis is desirable.22e25 However, we acknowledge
that continued expansion of self-expandable stents might
hamper comparison of immediate post-procedural results
with follow-up imaging.
Moreover, intravascular ultrasound (IVUS) measure-
ments indicating 50% diameter stenosis or 75% area
stenosis can be used to determine restenosis.
Due to the less invasive character of the examination
along with ethical considerations regarding serial intra-
arterial angiography for study purposes, we recognize
duplex ultrasonography for detection of binary restenosis.
Unfortunately, duplex ultrasonography can be associated
with a considerable inter- and intraobserver variability,
especially in vessels as heterogeneous as the iliac and be-
low-the-knee arteries,26,27 and, as opposed to angiography,
does not help in precisely quantifying the percentage of
stenosis in lower limb arteries.28 Therefore, inter- and
intra-observer variability of the performing ultrasound
Uniform Reporting Studies for Peripheral Endovascular Revascularization 417laboratory and core laboratory assessment should be in-
cluded in the report. For uniform reporting standards, we
suggest to define binary restenosis on duplex ultrasonogra-
phy by a peak systolic velocity ratio greater than 2.4 at the
target lesion as initially proposed by Ranke.18 Moreover, we
recommend the use of rulers to document the exact dis-
tance of the lesion from anatomical landmarks (such as
the patella or the iliac or femoral bifurcation) at baseline
and during follow-up visits. Formal instruction by the inde-
pendent core lab to the sites on the annotation of duplex
ultrasound images to insure accurate image location to tar-
get lesion must be routine and clearly described.
Magnetic resonance and computed tomography angiog-
raphy might become valuable tools in morphological follow-
up after endovascular interventions. However, dedicated
studies assessing their accuracy are currently lacking.
If non-angiographic modalities are used for follow-up,
they must be compared to the same modality over time.
Since the terms primary patency, primary assisted
patency, and secondary patency are mainly used in surgical
trials10 and their use may be confusing after endovascular
therapy, we propose, in accordance with coronary trials,
the following terminology to describe need for re-interven-
tions: Rates of repeated target lesion revascularization
(TLR) should be reported in surviving patients with
preserved limb to express the frequency of the need for
repeated procedures (endovascular or surgical) due to
a problem arising from the lesion (þ1 cm proximally and
distally to include edge phenomena) initially treated.
Repeated target extremity revascularization (TER) should
be reported in surviving patients with preserved limb to ex-
press the frequency of the need for repeated procedures
(endovascular or surgical) due to a problem arising remote
from the lesion initially treated. A subtraction of TLR from
TER rates yields the rate of revascularizations performed
due to progression of atherosclerosis.
Device-specific problems such as stent fractures should
be reported according to specific standards.29Statistical Analysis
Number of patients lost to follow-up should not exceed 5%
at 12 months and reasons for loss of follow-up should be
noted.
Procedural success should be reported both on an
intention-to-treat and on per-protocol analysis.
A prospective randomized controlled study design
should be preferred to reliably assess the efficacy of endo-
vascular revascularization.
Treatment outcomes should be based on the intent to
treat and must include all patients who consent to undergo
the procedure.
Except for analysis of technical success, periprocedural
complications, and quantitative angiographic outcomes,
the above-mentioned endpoints should be calculated using
cumulative analyses (i.e. according to the life-table
method30) or according to the method proposed by
Kaplan-Meier.31 Thus, patients who have reached specific
clinical endpoints (e.g. repeated TLR) should be uncen-
sored within this cumulative analysis and also be excluded
from further follow-up assessments such as ABI comparisonsor descriptions of clinical stage beyond the time of uncen-
soring. Dead patients should be censored on the day
between the time point when they were last examined
and the actual date of death.
Patients undergoing further revascularizations outside
the initially treated target lesion (repeated TER) should not
be uncensored since this represents a progression of
atherosclerosis rather than a failure of the treatment of
the initially treated lesion.
Conclusions
With the present consensus document the DEFINE group
aimed to establish definitions as a point of reference for
future clinical trials. Particular care was taken to define
clinical outcomes from a patient’s perspective. Impor-
tantly, clinical outcome definitions can be equally applied
to future trials comparing endovascular and open surgical
revascularization for chronic lower limb ischemia. These
definitions represent mandatory requirements to obtain
comparability of studies dealing with endovascular therapy
of peripheral arteries to further elucidate and prove long-
term credibility of this method. Adherence to these
definitions is recommended for future publications.Acknowledgement
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Grade Category Clinical description Objective criteria
IIIa 5 Minor tissue loss -
nonhealing ulcer,
focal gangrene
with diffuse pedal
ischemia
Resting AP
<60 mm Hg, ankle
or metatarsal PVR
flat or barely
pulsatile; TP
<40 mm Hg
6 Major tissue loss -
extending above
TM level, functional
foot no longer
salvageable
Same as category 5
AP, Ankle pressure; PVR, pulse volume recording; TP, toe pres-
sure; TM, transmetatarsal.
a Grades II and III, categories 4, 5, and 6, are embraced by the
term chronic critical ischemia.
b Five minutes at 2 mph on a 12% incline.
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Clinical categories of chronic limb ischemia
according to Rutherford 3
Grade Category Clinical description Objective criteria
0 0 Asymptomatic - no
hemodynamically
significant occlusive
disease
Normal treadmill
or reactive
hyperemia test
1 Mild claudication Completes
treadmill exerciseb;
AP after exercise
>50 mm Hg but at
least 20 mm Hg
lower than resting
value
I 2 Moderate claudication Between
categories 1 and 3
3 Severe claudication Cannot complete
standard treadmill
exerciseb and AP
after exercise
<50 mm Hg
IIa 4 Ischemic rest pain Resting AP
<40 mm Hg, flat or
barely pulsatile
ankle or metatarsal
PVR; TP <30 mm HgReferences
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